Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane

Breast Cancer

Volumn 18, Issue 3, 2011, Pages 182-188

  Okanami, Yuko ^a,b   Ito, Yoshinori ^a   Watanabe, Chie ^a   Iijima, Kotaro ^a   Iwase, Takuji ^a   Tokudome, Nahomi ^a   Takahashi, Shunji ^a   Hatake, Kiyohiko ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anthracycline; Chemotherapy induced amenorrhea; Taxane

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE;

ADULT; AGE DISTRIBUTION; AMENORRHEA; ARTICLE; BODY TEMPERATURE DISORDER; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DEPRESSION; DRUG INDUCED HEADACHE; FEMALE; HEALTH SURVEY; HEART PALPITATION; HOT FLUSH; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; PREMENOPAUSE; PRIORITY JOURNAL; QUESTIONNAIRE;

ADULT; AMENORRHEA; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 81855175326     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-011-0256-7     Document Type: Article

References (27)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687-1717.
2. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;114:1718-29.
3. Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22:4174-83.
4. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: Overview of the randomised trials. Lancet. 1996;348:1189-96.
5. Pagani O, O'Neill A, Castiglione M, Gelber RD, Goldhirsch A, Rudenstam CM, et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer. 1998;34: 632-40.
6. Bianco AR, Del Mastro L, Gallo C, Perrone F, Matano E, Pagliarulo C, et al. Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer. 1991;63:799-803.
7. Warne GL, Fairley KF, Hobbs JB, Martin FI. Cyclophosphamideinduced ovarian failure. N Engl J Med. 1973;289:1159-62.
8. Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at MD Anderson Hospital and Tumor Institute. NCI Monogr. 1986;1:105-9.
9. Swain SM, Land SR, Ritter MW, Costantino JP, Cecchini RS, Mamounas EP, et al. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide- followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat. 2009;113: 315-20.
10. Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients: the International Breast Cancer Study Group. Ann Oncol. 1990;1:183-8.
11. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17:2365-70.
12. Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol. 2006;24:2651-8.
13. Han HS, Ro J, Lee KS, Nam BH, Seo JA, Lee DH, et al. Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Treat. 2009;115:335-42.
14. Berliere M, Dalenc F, Malingret N, Vindevogel A, Piette P, Roche H, et al. Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel. BMC Cancer. 2008;8: 56-64.
15. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;15:976-83.
16. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302-13.
17. Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol. 2007;30:126-32.
18. Fornier MN, Modi S, Panageas KS, Norton L, Hudis C. Incidence of chemotherapy-induced, long-terme amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer. 2005;104:1575-9.
19. Davis L, Klitus M, Mintzer D. Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes. Clin Breast Cancer. 2005;6:421-4.
20. Abusief ME, Missmer SA, Ginsburg ES, Weeks JC, Partridge AH. The effects of pacritaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer. 2010;116:791-8.
21. Reh A, Oktem O, Oktay K. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril. 2008;90:1635-9.
22. Di Cosimo S, Alimonti A, Ferretti G, Sperduti I, Carlini P, Papaldo P, et al. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann Oncol. 2004;15:1065-71.
23. Bordeleau L, Pritchard K, Goodwin P, Loprinzi C. Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. Clin Ther. 2007;29:230-41.
24. Leining MG, Gelber S, Rosenberg R, Przypyszny M, Winer EP, Partridge AH. Menopausal-type symptoms in young breast cancer survivors. Ann Oncol. 2006;17:1777-82.
25. Nystedt M, Berglund G, Bolund C, Fornander T, Rutqvist LE. Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol. 2003;21:1836-44.
26. Gerber B, Stehle H, Ricardo F, Maass N, Fischer D, Sommer HL et al. A prospective randomized multicenter study to prevent chemotherapy-induced ovarian failure with the GnRH-agonist goserelin in young hormone-insensitive breast cancer patients receiving anthracycline containing (neo-) adjuvant chemotherapy (GBG 37). J Clin Oncol. 2009;27:Abstr No. 526.
27. Burger HG. The endocrinology of the menopause. Maturitas. 1996;23:129-36.